TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I) (TaPaS)
Primary Purpose
Overactive Bladder Syndrome
Status
Terminated
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
TTNS
TTNS Sham
Sponsored by
About this trial
This is an interventional treatment trial for Overactive Bladder Syndrome
Eligibility Criteria
Inclusion Criteria:
- Children between 5 and 12 years old, clinically diagnosed with the idiopathic overactive bladder syndrome with urinary incontinence (daytime and/or nighttime)
- Untreated, except from urotherapy.
Exclusion Criteria:
- Enuresis nocturna due to nocturnal polyuria
- Dysfunctional voiding
- Neurogenic bladder
- Psychiatric disorders, behavioural disturbances or mental disabilities
- Treated before with pharmacotherapy or invasive therapies for OAB
- Children with parents unable to record reliably micturition diaries.
Sites / Locations
- University Hospital Ghent
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
Active TTNS
TTNS sham intervention
Arm Description
Children treated by transcutaneous tibial nerve stimulation. TENS device connected to adhesive electrodes. Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
Children treated by TTNS with same positioning as the active TTNS treatment. Stimulation settings: 200 µS, 20 Hz, 0-1 V. Patients and parents will be told that electric currence is given, but that no sensation will be feld. Home therapy: Daily stimulation during 60 minutes.
Outcomes
Primary Outcome Measures
Mean voided volume per void
Difference in mean voided volume per void in percentage
Secondary Outcome Measures
Maximum voided volume (ml)
Maximal voided volume per void ( ml) .
Number of urgency incontinence episodes / 24 h.
Reduction in number of incontinence episodes per 24 hour
Daytime voiding frequency
Mean voiding frequency per day
Satisfaction on urinary symptoms reported by parents
Subjective satisfaction reported by the parents - on a 7 point likert scale- "How satisfied of dissatisfied would you be if the bladder symptoms of your child would persist like this?
Time to recurrence
Time to complete or partial relapse to baseline symptoms after 12 weeks of treatment during the observational period of 6 weeks.
Full Information
NCT ID
NCT04256876
First Posted
January 15, 2020
Last Updated
January 2, 2023
Sponsor
University Hospital, Ghent
1. Study Identification
Unique Protocol Identification Number
NCT04256876
Brief Title
TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I)
Acronym
TaPaS
Official Title
A Randomized-controlled Trial Comparing Transcutaneous Tibial Nerve Stimulation (TTNS) Versus Sham Therapy on Short Term Continence Outcomes in Children With the Idiopathic Overactive Bladder Syndrome: the TaPaS Trial Part I
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Terminated
Why Stopped
due to the corona pandemic, live patient contact was no longer possible. As a result, the study had to be stopped early.
Study Start Date
November 7, 2018 (Actual)
Primary Completion Date
July 1, 2020 (Actual)
Study Completion Date
July 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Ghent
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
Part I of the TaPaS trial forms part of a twofold clinical RCT:
Part 1) A prospective RCT comparing the efficacy of transcutaneous tibial nerve stimulation (TTNS) with TTNS sham therapy for children with idiopathic overactive bladder on clinical and patient reported outcomes (PROMS).
Part 2) A prospective RCT comparing TTNS versus Percutaneous tibial nerve stimulation (PTNS) on clinical outcomes and PROMS.
Detailed Description
Non invasive neuromodulation therapy for children with the overactive bladder syndrome is a highly under investigated topic in medical literature.
Only 2 studies ( Patidar et al. and Boudaouid et al.) investigated the use of tibial nerve stimulation with adhesive electrodes.
1) In the first trial the superiority of TTNS vs.Sham therapy for the therapeutic management of children with OAB naive to any pharmacological treatment will be examined.
Clinical outcomes will be assessed by the use of daytime and nighttime bladder diaries.
Assessment of outcomes at baseline, after 6 weeks and 12 weeks of treatment, and investigation of mean time to partial or complete relapse following 6 weeks observation.
After a wash-out period of 6 weeks, patients from the part I Sham group will be able to be included for TaPaS part II.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overactive Bladder Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective randomized-controlled superiority trial:
TTNS(Active treatment) vs. Sham TTNS (placebo)
Masking
ParticipantOutcomes Assessor
Masking Description
Participants are blinded for the given treatment ( Active TTNS vs. Sham TTNS) by the care provider ( Physiotherapist).
The outcomes assessor (the pediatric urologist) isn't aware of the treatment neither.
Allocation
Randomized
Enrollment
6 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Active TTNS
Arm Type
Active Comparator
Arm Description
Children treated by transcutaneous tibial nerve stimulation. TENS device connected to adhesive electrodes. Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
Arm Title
TTNS sham intervention
Arm Type
Sham Comparator
Arm Description
Children treated by TTNS with same positioning as the active TTNS treatment. Stimulation settings: 200 µS, 20 Hz, 0-1 V. Patients and parents will be told that electric currence is given, but that no sensation will be feld.
Home therapy: Daily stimulation during 60 minutes.
Intervention Type
Device
Intervention Name(s)
TTNS
Other Intervention Name(s)
Transcutaneous tibial nerve stimulation
Intervention Description
See section 'arms' Stimulation settings: 200 µS, 20 Hz, 1-20 V ( depending of sensory response) Home-therapy: Daily stimulation during 60 minutes.
Intervention Type
Device
Intervention Name(s)
TTNS Sham
Other Intervention Name(s)
Sham therapy
Intervention Description
See section 'arms'
Primary Outcome Measure Information:
Title
Mean voided volume per void
Description
Difference in mean voided volume per void in percentage
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Maximum voided volume (ml)
Description
Maximal voided volume per void ( ml) .
Time Frame
12 weeks
Title
Number of urgency incontinence episodes / 24 h.
Description
Reduction in number of incontinence episodes per 24 hour
Time Frame
12 weeks
Title
Daytime voiding frequency
Description
Mean voiding frequency per day
Time Frame
12 weeks
Title
Satisfaction on urinary symptoms reported by parents
Description
Subjective satisfaction reported by the parents - on a 7 point likert scale- "How satisfied of dissatisfied would you be if the bladder symptoms of your child would persist like this?
Time Frame
12 weeks
Title
Time to recurrence
Description
Time to complete or partial relapse to baseline symptoms after 12 weeks of treatment during the observational period of 6 weeks.
Time Frame
At 12 weeks of treatment + at 6 weeks of observational period without treatment.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Children between 5 and 12 years old, clinically diagnosed with the idiopathic overactive bladder syndrome with urinary incontinence (daytime and/or nighttime)
Untreated, except from urotherapy.
Exclusion Criteria:
Enuresis nocturna due to nocturnal polyuria
Dysfunctional voiding
Neurogenic bladder
Psychiatric disorders, behavioural disturbances or mental disabilities
Treated before with pharmacotherapy or invasive therapies for OAB
Children with parents unable to record reliably micturition diaries.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne-Françoise Spinoit, Professor
Organizational Affiliation
University Hospital, Ghent
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Ghent
City
Gent
State/Province
East-Flanders
ZIP/Postal Code
9000
Country
Belgium
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
25979217
Citation
Boudaoud N, Binet A, Line A, Chaouadi D, Jolly C, Fiquet CF, Ripert T, Merol ML. Management of refractory overactive bladder in children by transcutaneous posterior tibial nerve stimulation: A controlled study. J Pediatr Urol. 2015 Jun;11(3):138.e1-10. doi: 10.1016/j.jpurol.2014.09.013. Epub 2015 Mar 31.
Results Reference
background
PubMed Identifier
26279104
Citation
Patidar N, Mittal V, Kumar M, Sureka SK, Arora S, Ansari MS. Transcutaneous posterior tibial nerve stimulation in pediatric overactive bladder: A preliminary report. J Pediatr Urol. 2015 Dec;11(6):351.e1-6. doi: 10.1016/j.jpurol.2015.04.040. Epub 2015 Jul 29.
Results Reference
result
PubMed Identifier
33810804
Citation
Ghijselings L, Renson C, Van de Walle J, Everaert K, Spinoit AF. Clinical efficacy of transcutaneous tibial nerve stimulation (TTNS) versus sham therapy (part I) and TTNS versus percutaneous tibial nerve stimulation (PTNS) (part II) on the short term in children with the idiopathic overactive bladder syndrome: protocol for part I of the twofold double-blinded randomized controlled TaPaS trial. Trials. 2021 Apr 2;22(1):247. doi: 10.1186/s13063-021-05117-8.
Results Reference
derived
Learn more about this trial
TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I)
We'll reach out to this number within 24 hrs